1	Erythropoietin single nucleotide polymorphisms are associated with anemia and
2	dyslipidemia in a cardiovascular disease population.
3	Victoria Northrup <sup>1,2,6</sup> , Ashley L. Eadie <sup>1,2,6</sup> , Victoria L. Nelson <sup>1,2,6</sup> , Kenneth D'Souza <sup>1,2,3,6</sup> , Ansar
4	Hassan <sup>3,6</sup> , Thomas Pulinilkunnil <sup>2,4,6</sup> , Petra Kienesberger <sup>2,4,6</sup> , Jean-Francois Légaré <sup>3,6</sup> , Jeremy A.
5	Simpson <sup>5,6</sup> , Keith R. Brunt <sup>1,2,3,6</sup>
6	<sup>1</sup> Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada
7	<sup>2</sup> Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada
8	<sup>3</sup> Departments of Cardiology & Cardiac Surgery, New Brunswick Heart Center,
9	Saint John Regional Hospital, Saint John, New Brunswick, Canada
10	<sup>4</sup> Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova
11	Scotia, Canada
12	<sup>5</sup> Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario,
13	Canada
14	<sup>6</sup> IMPART investigator team Canada (https://impart.team/)
15	
16	Corresponding Author:
17	Dr. Keith R. Brunt
18	100 Tucker Park Road, Box 5050
19	Saint John, NB, Canada, E2L 4L5
20	1-(506)-636-6974
21	keith.brunt@dal.ca
22	@prof_brunt (social media)
23	
24	
25	

## 26 Abstract

27 Human erythropoietin (EPO) is an essential erythropoietic cytokine and recombinant biological 28 therapeutic in anemia in chronic kidney disease. Single nucleotide polymorphisms (SNPs) in 29 EPO have been linked to anemia and diabetic microvascular complications but no other 30 cardiovascular comorbidities like dyslipidemia or hypertension. Here identified a clinical cohort 31 of cardiovascular patients with anemia, dyslipidemia, hypertension, type-2 diabetes, or heart 32 failure with preserved ejection fraction. Sanger sequencing was used for genotyping three EPO 33 SNPs (rs1617640, rs507392 and rs551238), which were compared to clinical outcomes with 34 SNPstat and clinical parameters profiles by student t-test. Nonstandard clinical chemistry measures of plasma EPO, hepcidin, transferrin, and ferritin were determined by ELISA. In the 35 36 additive model, the C allele of rs1617640 was associated with lower EPO and anemia. In the 37 recessive model, the SNP rs507392 genotype of GG was associated with dyslipidemia, which 38 was associated with lower EPO in plasma and elevated total cholesterol and low-density 39 lipoproteins. Interestingly, the G allele of rs507392 was found to be associated with 40 hypertension, but only in females. Here we show that the SNPs in EPO are a potential risk factor 41 for anemia, dyslipidemia, and hypertension in cardiovascular disease patients. 42

## 43 Introduction

44

45	Cardiovascular disease is one of the leading causes of death worldwide[1], with multiple
46	contributing risk factors like anemia, including some linked to erythropoietin (EPO) or the use of
47	erythropoietic stimulating agents.[2] Heart failure with preserved ejection fraction (HFpEF), is
48	an especially challenging multimorbid condition featuring anemia, hypertension, type-2 diabetes
49	mellitus (T2DM), obesity, or chronic kidney disease. The underlying cause of HFpEF and
50	optimal medical management remains a challenge[1]. Microvascular complications are typically
51	reported in HFpEF[3], and anemia in heart failure is generally associated with higher
52	mortality,[4] severity, and hospital admission rates[5,6]. HFpEF is also more common in
53	females, particularly those who are older, obese, and with a higher New York Heart Association
54	(NYHA) classification. Microvascular complications in diabetes and anemia have been linked to
55	EPO but have not previously been investigated in HFpEF or its multimorbid feature
56	comorbidities.
57	EPO is a master regulator of hematopoiesis and erythropoiesis, with secondary roles in
58	cytoprotection and cellular metabolism.[7] Research on EPO has been extensive, yet clinical
59	variation in EPO expression in health and disease and the underlying secondary mechanisms are

60 poorly understood. A significant source of clinical variation in hormones like EPO can occur

61 with haplotypes or single nucleotide polymorphisms (SNP). The entire gene of EPO has been

62 known for decades, yet just three SNP have been identified as clinically relevant

63 rs1617640(promoter), rs507392(intron) and rs551238(downstream). Genome-wide association

64 studies (GWAS) and expression quantitative trait loci (eQTL) analysis have previously

established that promoter SNP (rs1617640) is associated with an alteration in serum EPO,[8] a

66 finding confirmed in healthy blood donors[9]. The promoter SNP (rs1617640) has also been

67	linked to diabetic microvascular complications[10-18], anemia in T2DM[19], and renal
68	dysfunction after cardiac surgery[20] (Supplemental Table 1). In intron 3, SNP rs507392 was
69	linked to diabetic microvascular complications [10,12,13,21] and overall higher mortality in
70	diabetics [9]. SNP rs551238 (downstream of EPO) has also been associated with microvascular
71	complications[9,10,12–15,21,22] and higher hematocrit in healthy blood donors [9]
72	(Supplemental Table 1). Together, this suggests a potential link between microvascular
73	complications, hematocrit, and EPO SNPs. These EPO SNPs have also been associated with
74	EPO serum levels[18]. In CKD, a decrease in EPO is associated with anemia[23], whereas in
75	other forms of anemia, EPO can be increased up to 100-fold, suggesting insensitivity in
76	molecular signaling.[24] Secondary risks to CVD might also be linked to EPO independent of
77	anemia, especially classic risk factors of CVD. For example, dyslipidemia is a salient risk factor
78	for CVD characterized by abnormal serum cholesterol levels, triglycerides and related
79	lipoproteins[25]. In mice treated with recombinant EPO (rhEPO), triglyceride levels were
80	decreased[26] and lipoprotein lipase (in lipogenesis) was elevated.[26,27] In humans, treatment
81	with rhEPO is associated with lower triglyceride levels and cholesterol in end-stage renal
82	failure.[28]
83	Although anemia, dyslipidemia, T2DM, hypertension are risk factors for CVD and
84	multimorbid features of HFpEF with evidence of being modifiable by rhEPO—only anemia has
85	been linked to EPO SNPs to date.[19] Here, we hypothesize that three EPO SNPs—
86	rs1617640(promoter), rs507292(intron) and rs551238(downstream)—correlate with EPO plasma

87 concentrations and are associated with either anemia, dyslipidemia, T2DM, hypertension and/or

88 HFpEF in a clinical population requiring surgical interventions for CVD.

89

# 90 Methods

### 91 Genomic DNA extraction

92	Genomic DNA (gDNA) was isolated from the buffy coat of blood collected during the
93	impact of Obesity on Postoperative Outcomes following cardiac Surgery (OPOS) study
94	(http://clinicaltrials.gov/study/NCT0324891). The OPOS cohort consisted of participants aged
95	18-75 years old who underwent elective cardiac surgery at either the New Brunswick Heart
96	Center in New Brunswick, Canada or the Maritime Heart Centre in Nova Scotia, Canada.[29]
97	The OPOS study and related biomarker discovery was approved by the Horizon Health Network
98	Research Ethics Board (#RS20142006: RS100835). The buffy coat was separated from blood,
99	and gDNA was isolated using either DNAzol <sup>®</sup> reagent (GibcoBRL cat $\#$ 10503-027) or
100	QIAamp® DNA blood mini (Qiagen cat # 51104) kits (following the manufacturer's protocol).
101	DNA was quantified by spectroscopy on a BioTek Synergy TM H4 Hybrid Microplate reader
102	using the 260:280 nm ratio by the Gen5 software (BioTek), and the average concentration of
103	technical duplicates was used.
104 105	Primer design Primers were designed using Oligo 7 software (Table 1).[30] Primers designed for gDNA
106	sequencing included M13 sequences[31] to facilitate Sanger sequencing and M13 primers were
107	used in sequencing reactions.
108	Polymerase Chain Reaction
109	End-point polymerase chain reaction (PCR) was performed on gDNA using AmpliTaq
110	Gold <sup>™</sup> 360 Master Mix (Applied Biosystems cat # 4398881). PCR reactions consisted of 1 X

111 AmpliTaq Gold<sup>TM</sup> 360 Master Mix, 0.3 μM of forward and reverse primers, 4 μg of Bovine

112 Serum Albumin (BSA, Thermo Scientific), 50 ng of gDNA and nuclease-free water up to  $15 \,\mu$ L.

113 Reactions were amplified on a Mastercycler Nexus Gradient Thermocycler (Eppendorf) using

- 114 the cycling conditions listed in Table 2.
- 115 PCR products were verified using 7500 Agilent DNA Chips (Agilent cat # 5067-1506) on

116 the Bioanalyzer 2100 system (Agilent). PCR products were cleaned up using 2 µL of ExoSAP-

- 117 IT<sup>TM</sup> (Applied Biosystems cat # 78200) in 5 μL of PCR product and incubating at 37°C for 15
- 118 minutes. ExoSAP-IT<sup>TM</sup> was inactivated at 80°C for 15 minutes.
- 119 Sanger Sequencing
- 120 Sequencing reactions were prepared using a BigDye<sup>™</sup> Terminator v3.1 Cycle
- 121 Sequencing Kit (Applied Biosystems cat# 4337457). The cleaned PCR product was added to a
- reaction of 1X Sequencing buffer, 1X BigDye<sup>™</sup> MasterMix, and 2µM primer of M13
- sequencing primers.[31] Sequencing reactions were incubated at 96°C for 1 minute and 25 cycles
- 124 of 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes.
- 125 BigDye<sup>TM</sup> Xterminator beads (Applied Biosystems cat # 4376486) were added to the
- sequencing reaction and vortexed at 2000 rpm for 25 minutes. Samples were centrifuged for 2
- 127 minutes at 2000 X rcf and let rest for 2 minutes before centrifuging again at 2000 X rcf for 30
- seconds, followed by another 30 seconds of rest to ensure that beads were sedimented. Then,
- 129 20µL of the sequencing reaction (without beads) was transferred to a 96-well plate and loaded
- 130 onto the 3500 Genetic Analyzer (Applied Biosystems) for sequencing.
- 131 Sanger Sequencing Analysis
- Sequences were analyzed using BioEdit Sequences Alignment Editor software.[32] The forward and reverse sequences were aligned using the ClustalW Multiple alignment tool to generate the consensus sequence for each product. Sequences were submitted to NCBI Blast to validate correct target amplification and were compared to the NCBI reference sequence

NG\_021471.2 to identify variants. A variant was defined as any base calling that differed fromthe reference sequence.

138 SNP analysis

139 SNPStats (www.snpstats.net)[33] was used to determine allele and genotype frequencies,

140 test for Hardy-Weinberg equilibrium, assess SNP response using logistic regression in multiple

141 inheritance models (co-dominant, dominant, recessive, over-dominant and log-additive), linkage

142 disequilibrium statistics, and for haplotype analysis. Analysis used sex, age, and body mass index

143 (BMI) as co-variants. A p-value < 0.05 was deemed significant.

144 Clinical findings were obtained from the OPOS BioBank (storing retrievable databases of

145 de-identified data abstracted from patient records). Comparisons of clinical values with genotype

146 were performed using a student t-test to determine the p-value (<0.05 significant). A

147 Kolmogorov-Smirnov test in GraphPad was used to confirm normality. A ROUT (Q=1) test in

148 GraphPad was used to determine outliers; outliers were still presented and identified by

149 encirclement in figures for clinical relevance but were otherwise excluded from group testing.

150 Enzyme-linked immunosorbent assays

151 Plasma samples collected from OPOS [29] were used for enzyme-linked immunosorbent assays

152 (ELISA) for EPO (Human EPO ELISA kit, Invitrogen Cat # BMS2035-3), Transferrin

153 (Transferrin Human ELISA Kit, Invitrogen cat # EHTF), Hepcidin (Human Hepcidin Quantikine

154 ELISA kit, R&D systems cat # DHP350) and Ferritin (Ferritin Human ELISA Kit, Invitrogen cat

155 # EHFTL). Plasma samples were diluted 1:2 for EPO, 1: 20,000 for Transferrin, 1:5 for

156 Hepcidin, and 1:10 for Ferritin using the kit manufacturer's diluent. ELISAs were performed

using the manufacturer's protocol and absorbance was measured at 450 nm using the Synergy

158 H4 plate reader. GraphPad Prism (Prism9) was used for statistical analysis and graphing data.

159 Two-way ANOVA was used to determine p-values. A p-value of <0.05 was deemed significant.

160 **Results** 

#### 161 Subcohort of patients with multimorbid conditions at elevated risk of CVD

The OPOS sub-cohort analyzed herein consisted of 95 participants recruited for the 162 163 OPOS study (358 participants). Participants with at least one condition: anemia, dyslipidemia, 164 hypertension, T2DM and/or diagnosed HFpEF, were sampled as a sub-cohort. The demographics 165 and clinical parameters of the OPOS cohort are shown in Table 3 and Supplemental Table 2. 166 Some multimorbid parameters overlap between controls and the cases in each condition but 167 otherwise served provided sex and age matched controls with CVD but without the specified 168 outcome. Among these cases, dyslipidemia were associated with a higher NYHA score. BMI was 169 higher in patients with T2DM and anemia but lower in those with HFpEF. Males were more 170 prevalent in T2DM, hypertension, and dyslipidemia sub-populations. In contrast, females were 171 more prevalent in anemia (taking into consideration the sex-dependent normal ranges used for 172 males/females of the study population). Overall, this subcohort represents patients with salient 173 risk factors requiring an intervention by cardiac surgery.

174

## 175 Reassurance of experimental approach for avoiding SNP linkage disequilibrium

SNPs rs1617640(promoter), rs507392(intron) and rs551238(downstream) are located
within 4.2 kb of one another. Due to this proximity, linkage disequilibrium is likely to occur[34].
Here, we performed a linkage disequilibrium analysis using SNPstats and found a high degree of
linkage disequilibrium between our three SNPs (Supplemental Figure 1a). The highest degree of
linkage disequilibrium was measured between rs1617640(promoter) and rs507392(intron),
followed by rs507392(intron) and rs551238(downstream). SNPs rs1617640(promoter) and

182	rs551238(downstream) were observed to have the least degree of disequilibrium. These
183	associations correlated with the SNPs' positions along the EPO gene, with those closest in
184	proximity (Supplemental Figure 1b) showing the highest degree of disequilibrium.
185	
186	The presence of the C allele in rs1617640(promoter) increases the risk of anemia

187 Each SNP was examined for association based on dominant, recessive, or additive 188 inheritance models (Table 4). The C allele of rs1617640 SNP in the promoter region was 189 associated with anemia in an additive inheritance model with an odds ratio (OR) of 1.96 (p-value 190 0.04). Whether clinical parameters correlated with specific genotypes was then investigated. In SNP rs1617640, there were significant differences between genotypes in hemoglobin, neutrophil 191 192 to lymphocyte ratios (NLR), cholesterol, low-density lipoprotein (LDL), and non-high-density 193 lipoprotein (non-HDL) (Supplemental Table 3, Supplemental Figure 2). The lower hemoglobin 194 levels in the CC genotype support the association of anemia with the C allele, with the higher 195 NLR suggesting elevated inflammation. The rs1617640(promoter) CC genotype was associated 196 with a lower plasma EPO level, although iron bioavailability (as measured by Ferritin, Hepcidin 197 and Transferrin) was not significantly different (Figure 1). These findings suggest that SNP 198 rs1617640(promoter) is likely affecting EPO directly, not through iron bioavailability.

199

### 200 GG Genotype of rs507392(intron) is protective against dyslipidemia

To characterize the role of the GG Genotype of intron SNP (rs507392) we examined the OR-value for anemia, dyslipidemia, and hypertension. The GG genotype of rs507392 was associated with protection against dyslipidemia in a recessive model (OR value = 0.29; p-value = 0.048) (Table 4), while there was no significance with anemia or hypertension. Variations based

205	on genotype in rs507392(intron) were seen in clinical parameters including cholesterol, LDL,
206	non-HDL, and NLR (Supplemental Table 4, Supplemental Figure 3). This suggests that SNP
207	rs507392(intron) is associated with lipid handling/regulation. As with rs1617640(promoter), the
208	GG genotype in rs507392(intron) demonstrated lower levels of EPO in the plasma (Figure 1).
209	There was no association to risk factors for SNP rs551238(downstream) (Table 4), and fewer
210	significant differences in clinical parameters were observed (Supplemental Table 5 and
211	Supplemental Figure 4). Unlike rs1617640(promoter) and rs507392(intron), no significant EPO
212	changes in rs551238(downstream) were observed (Figure 1).
213	
214	No strong evidence for EPO haplotype association with risk factors
215	Haplotype was also examined to determine the cumulative effects of all three SNPs to
216	clinical outcomes. The predominant haplotypes of AAT and CGG did not correlate with any
217	clinical phenotype. However, one of the rare haplotypes of CGT (which occurred in
218	approximately 3% of our cohort) did correlate with dyslipidemia. The OR-value of 0.05 suggests
219	that the CGT haplotype is protective against dyslipidemia but should be interpreted with caution
220	given the low prevalence (Table 5, Supplemental Table 6).
221	
222	Sex differences are apparent with SNP associations to risk factors
223	Precision medicine necessitates accounting for sex differences, and here we find
224	meaningful sex effects to the associated risk factors. In males, the prevalence of dyslipidemia,
225	T2DM, and hypertension are significantly higher than that observed in females[35], whereas in
226	females, the prevalence of anemia[36] and HFpEF[37] is significantly higher. Given these sex
227	differences in the clinical phenotypes examined herein, we analyzed the differences in SNPs

228	within each sex to determine if sex differences would affect our results. SNP rs507392(intron)
229	AG and GG genotypes, and rs551238(downstream) TG genotype, were associated with
230	hypertension in females, but not in males (Table 6, Supplemental Table 7), suggesting that the
231	rs507392(intron) and rs551238(downstream) SNPs could be risk factors for hypertension in
232	females but not males.
233	
234	New EPO variants of potential concern identified
235	During the analysis of <i>a priori</i> sequences obtained for rs1617640(promoter),
236	rs507392(intron), and rs551238(downstream), other variants were also identified (Supplemental
237	Table 8). Many of these variants were only detected in a single individual as a heterozygote;
238	others were identified in a several individuals, with most being heterozygotes. However, most of
239	these variants have not previously been reported and are, therefore, of unknown significance.
240	Three variants were found in a significant subset of our population, including a four-base pair
241	deletion (2167?-2170?del). This variant is located within a repeat region in intron 3, and thus the
242	breakpoint may be inexact. This base pair deletion was found to be homozygous in 76 cases and
243	suspected to be heterozygous in 4 cases. The 3154T>G substitution was found in 83 individuals,
244	with 77 of these determined as homozygotes. Lastly, 3806T>C was found in 33 individuals, with
245	31 of these determined as heterozygotes. This data suggests more variation in EPO than
246	previously reported, which needs further exploration in larger study populations where further
247	associations can be uncovered.
248	

## 249 Discussion

250 Here, we identified linkage between the three EPO SNPs and cardiovascular disease risk 251 factors, including dyslipidemia and HFpEF-associated comorbidities: anemia, T2DM, and 252 hypertension. The CC genotype of rs1617640(promoter) and GG genotype of rs507392(intron) 253 were associated with lower EPO plasma levels and correlated with comparably higher 254 cholesterol, LDL, and non-HDL lipoproteins. The promoter-SNP (rs1617640) CC was associated 255 with lower Hb and anemia in a log additive model and has been previously linked to anemia in 256 T2DM[19]. While the role of the promoter-SNP in CVD has been explored to a lesser extent, our 257 data support it as being linked to anemia in CVD. Surprisingly, the intron-SNP (s507392) GG genotype had a protective association with dyslipidemia in a recessive model. There was no 258 259 significant association between hypertension and the SNPs in the overall population, although 260 rs507392(intron) and rs551238(downstream) were associated with hypertension in females, 261 suggesting a sex dependence. Our study highlights that EPO variants are associated with 262 comorbid conditions that present significant cardiovascular risk factors of anemia, dyslipidemia, 263 and hypertension for the first time.

EPO levels are well known to be associated with anemia[23,24], so any SNP that alters plasma EPO levels, such as rs1617640(promoter) and rs507392(intron), as we have shown, could be risk factors for anemia, and require additional pharmacogenetic guided intervention. Yet, iron bioavailability also contributes to two of the most common forms, iron-deficiency anemia and anemia of inflammation (or anemia of chronic disease, e.g., CVD)[38]. The

rs1617640(promoter) C-allele associated with anemia was also associated with NLR, indicative

of active inflammatory processes[39,40]. This suggests the C allele for rs1617640(promoter) is

associated with inflammation and decreased Hb. It has been purported that EPO can exert an

272 indirect anti-oxidant effect by utilizing iron in erythrocytosis resulting in less bioavailable 273 iron.[41] Patients with anemia of inflammation commonly have reduced serum iron and normal 274 to elevated iron stores.[42] In blood, iron is transported by transferrin[43] and can be stored in 275 ferritin within most cells, like macrophages and hepatocytes.[44] The release of recycled iron 276 from intracellular stores is partially regulated by hepcidin—a hormone that inhibits the 277 transportation of intracellular iron to the blood and is induced by inflammation.[38] Hypoxia-278 inducible factors (HIFs; which upregulate EPO[7]) also reduce hepcidin, thus increasing 279 transferrin, ferritin, and iron bioavailability.[45] We measured hepcidin, transferrin and ferritin to 280 examine whether the EPO SNPs altered iron bioavailability. Still, despite elevated NLR associated with allelic frequency, we did not find significant differences between genotypes. This 281 282 leads us to conclude that the SNPs in *EPO* are likely not exerting their effects by regulating iron 283 bioavailability.

284 Ours is the first study to identify EPO SNPs associated with dyslipidemia and/or 285 lipoproteins in medically managed patients. Prior studies have reported that rhEPO therapy 286 modulates triglycerides, cholesterol, and other lipoproteins [26-28]. In a mouse model of CKD, 287 treatment with rhEPO resulted in decreased triglycerides, cholesterol and LDL, but not HDL[26]. 288 In the present study, the GG genotype of rs507392(intron) correlated with lower EPO 289 concentrations but increased cholesterol, LDL and non-HDL. These variations would also be 290 expected with diagnosed dyslipidemia, yet the GG genotype was associated with resistance to 291 dyslipidemia. This apparent contradiction is, however, more likely a consequence of medical 292 management of dyslipidemia (e.g., statins) to lower lipoprotein levels [46], not the association to 293 the clinical outcome. Future studies could be designed to validate this epidemiologically with 294 sufficient covariant adjustments. While rs1617640(promoter) and rs551238(downstream) did not

295	associate with dyslipidemia as an outcome, there was significant variation in cholesterol, with
296	the rs1617640(promoter)AC variant genotype being significantly lower for LDL and non-HDL
297	lipoproteins. The rs551238(downstream) TG variant was significantly associated with lower
298	cholesterol and non-HDL. The CGT haplotype was found to be protective against dyslipidemia,
299	but this was a rare finding (less than 3% of cohort) and should be interpreted with caution.
300	Together, these results show that EPO SNPs influence lipid metabolism and that
301	rs507392(intron) is associated with dyslipidemia. The fundamental biology and molecular
302	biology of EPO in these processes need to be explored further.
303	Many clinical phenotypes, including those examined here, have sex differences
304	attributable to prevalence, response to treatment, or clinical outcomes. Hypertension did not
305	show an association with the SNPs with the sexes combined, yet the presence of the G allele in
306	rs507392(intron) and the TG genotype in rs551238(downstream) showed an elevated risk in
307	females but not males. Hypertension is more prevalent in males[35], and our cohort contained
308	more males than females, which might explain why this association was initially masked. The
309	relationship between estrogen and the renin-angiotensin-aldosterone system (RAAS) is thought
310	to be one of the main reasons for the sex differences observed in hypertension. The RAAS has
311	also been found to be modulated by EPO: in Wistar rats, rhEPO increases renin[47] and in
312	isolated rat kidneys, rhEPO promotes angiotensin II (AngII) production.[48] In the oviduct and
313	endometrium, estrogen (17 $\beta$ (E2)) can also promote the expression of <i>EPO</i> .[49,50] Given the
314	relationship between EPO and the RAAS system by estrogen, this could be a potential
315	mechanism for why the G allele of rs507392 and TG genotype of rs551238 are risk factors for
316	hypertension just in females. Although this finding does require validation in a larger cohort
317	(including more females with a direct assessment of sex hormones), this may be a significant

318 finding since hypertension tends to be a more salient risk factor for CVD in females.[51] 319 Our results suggest that EPO SNPs may be associated with risk factors and comorbidities of CVD by affecting the amount of EPO produced. Given the ability to modulate the 320 321 amount of EPO either directly through rhEPO or indirectly by targeting upstream of EPO using 322 hypoxia-inducible factor prolyl-hydroxylase inhibitors, these SNPs could be used to inform the 323 best course of medical management. Hypoxia-inducible factor (HIF) prolyl-hydroxylase 324 inhibitors increase EPO by stabilizing the HIFs that transcriptionally act upon EPO DNA under 325 normoxic conditions. [52,53] Though not yet established, should EPO SNP result in less HIF 326 binding to EPO in transcriptional regulation or stability of the intronic stores of EPO mRNA[54], 327 then the use of HIF prolyl-hydroxylase inhibitors may be less potent for directly increasing EPO 328 compared to rhEPO. Although more work is needed before these SNPs are applied clinically, 329 they could guide pharmacogenetic interventions that seek to increase EPO or address anemia in 330 the future or reclassify existing clinical trial data for subgroup analyses. In addition to the 331 principally known SNPs, we also identified novel variants. Most occurred as heterozygotes in a 332 single individual, but four occurred in multiple individuals and are potential polymorphisms. In 333 clinical care, sequencing is more commonplace because of the integration of next-generation 334 sequencing technologies into standard care. In other disorders, this led to increased variant 335 detection.[55] Surprisingly, EPO has long been overlooked on many gene arrays or panels, 336 which may account for the low prevalence of *EPO* variants in the literature. As the sequencing 337 of *EPO* increases, we anticipate further variants of concern can be detected, with a potential for 338 linkages in large epidemiology studies now that we have discovered them. 339 Our study is not without limitations. One was the small sample size and depth of patient

340 file analyses, which did not allow us to account for many covariates (such as ethnicity, other

341 comorbidities, or medical management) that could affect our results. Our study did identify 342 dyslipidemia as a novel disorder and can direct further focused sequencing toward cases of 343 dyslipidemia and potentially investigate use/efficacy of statins as a covariant. Additionally, 344 hypertension was identified in females but not males, with the rs507392 G allele and rs551238 345 TG genotype being risk factors. As we had relatively few females, more sequencing should target 346 females with hypertension. Even with our sample size, we have identified variables that can 347 benefit epidemiological or database studies to validate clinical relevance, screening risk or 348 precision medical management. 349 Here, we have established that EPO SNP rs1617640 C-allele was associated with anemia, as well as changes in lipid metabolism and inflammation. We show the association of GG 350 351 genotype for rs507392 to dyslipidemia for the first time. This genotype indicates effects on lipid 352 profiles despite standard care. In females only, we show that the rs507392 and rs551238 EPO 353 SNPs are associated with hypertension. Together, our results suggest that SNPs in EPO are 354 involved in Hb regulation, lipid metabolism, and inflammation with a female-specific effect on 355 blood pressure.

356

#### 357 Acknowledgements

358 Blood samples for gDNA and clinical data were obtained from the IMPART BioBank

359 (https://impart.team/biobank/). Clinical data and samples were retrieved by IMPART BioBank
360 staff, including Dr. Christie Aguiar, Angella Mercer, and Saumil Shah, in collaboration with the

authors who extend their appreciation. The IMPART BioBank was supported by endowed funds

362 from the Dalhousie Medical Research Foundation and specialized equipment provided by Saint

363 John Regional Hospital Foundation-directed donation. This study was supported by the Natural

- 364 Sciences and Engineering Research Council (NSERC) [discovery grant #RGPIN-2018-05626]
- and # RGPIN-(2020)-04878] (JAS & KRB), Heart & Stroke Foundation of New Brunswick and
- 366 the generosity of the Chesley Family Grant (KRB). VN was supported by the NSERC Alexander
- 367 Graham Bell Canada Graduate Scholarship-Doctoral (CGS-D) and the New Brunswick Health
- 368 Research Foundation Beatrice Hunter Cancer Research Training Program Award.

### 369 Authorship Contributions

- 370 Conceived; designed experimental approaches of the study (VN, JAS, KRB); Mentored trainee
- acquisition of data and execution of the study (JAS & KRB); Collected and assembled data for
- the study (VN, ALE, VLN, KD, AH, TP, PK, JFL, & KRB); Analyzed; interpreted & reported
- data (VN, AE, VLN, & KRB); Drafted manuscript (VN & KRB); critically reviewed, revised and
- are edited manuscript for intellectual content and approved final work (VN, ALE, VLN, KD, JFL,
- 375 JAS, & KRB).

### 376 Disclosure of Conflict of Interest

- 377 At the time of study and reporting, KRB declares equity holdings in Fibrogen Inc. and serves as
- 378 director and majority shareholder in NBBM Inc.

379

#### 380

### 381 References

- 382 1 Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev
- 383 2017;**03**:7. doi:10.15420/CFR.2016:25:2
- 384 2 Jean-Baptiste W, Yusuf Ali A, Inyang B, et al. Are There Any Cardioprotective Effects or
- 385 Safety Concerns of Erythropoietin in Patients With Myocardial Infarction? A Systematic
- 386 Review. *Cureus* 2022;14. doi:10.7759/CUREUS.25671
- 387 3 Bilak JM, Alam U, Miller CA, *et al.* Microvascular Dysfunction in Heart Failure with
- 388 Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis.
- 389 *Card Fail Rev* 2022;**8**. doi:10.15420/CFR.2022.12
- Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is
- associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset
- 392 heart failure. *Circulation* 2003;**107**:223–5. doi:10.1161/01.CIR.0000052622.51963.FC
- 393 5 Silverberg DS, Wexler D, Blum M, *et al.* The cardio renal anemia syndrome: correcting
- anemia in patients with resistant congestive heart failure can improve both cardiac and
- renal function and reduce hospitalizations. *Clin Nephrol* 2003;**60 Suppl** 1:S93-102.
- 396 6 Caramelo C, Justo S, Gil P. Anemia in Heart Failure: Pathophysiology, Pathogenesis,
- 397 Treatment, and Incognitae. *Rev Española Cardiol (English Ed* 2007;**60**:848–60.
- 398 doi:10.1016/S1885-5857(08)60029-8
- 399 7 Bunn HF. Erythropoietin. *Cold Spring Harb Perspect Med* 2013;**3**:a011619.
- doi:10.1101/cshperspect.a011619
- 401 8 Harlow CE, Gandawijaya J, Bamford RA, et al. Identification and single-base gene-
- 402 editing functional validation of a cis-EPO variant as a genetic predictor for EPO-

- 403 increasing therapies Graphical abstract Authors. Published Online First: 2022.
- 404 doi:10.1016/j.ajhg.2022.08.004
- 405 9 Khabour OF, Bani-Ahmad MA, Hammash NM. Association between polymorphisms in
- 406 erythropoietin gene and upper limit haematocrit levels among regular blood donors.

407 *Transfus Clin Biol* 2012;**19**:353–7. doi:10.1016/J.TRACLI.2012.10.001

- 408 10 Abhary S, Burdon KP, Casson RJ, et al. Association between erythropoietin gene
- 409 polymorphisms and diabetic retinopathy. *Arch Ophthalmol* 2010;**128**:102–6.
- 410 doi:10.1001/archophthalmol.2009.355
- 411 11 Alwohhaib M, Alwaheeb S, Alyatama N, et al. Single nucleotide polymorphisms at
- 412 erythropoietin, superoxide dismutase 1, splicing factor, arginine/serin-rich 15 and
- 413 plasmacytoma variant translocation genes association with diabetic nephropathy. Saudi J

414 *Kidney Dis Transpl* 2014;**25**:577–81. doi:10.4103/1319-2442.132190

- 415 12 Fan YF, Fu YY, Chen Z, et al. Gene-gene interaction of erythropoietin gene
- 416 polymorphisms and diabetic retinopathy in Chinese Han. *Exp Biol Med* 2016;**241**:1524–
- 417 30. doi:10.1177/1535370216645210
- 418 13 Kaur N, Singh IR, Vanita V. Association of Erythropoietin Gene Polymorphisms With
- 419 Type 2 Diabetic Retinopathy in Adult Patients From Northern India. *Can J Diabetes*
- 420 2021;45:785–91. doi:10.1016/j.jcjd.2021.03.008
- 421 14 Li H, Xu H, Li Y, *et al.* Associations between erythropoietin polymorphisms and risk of
- diabetic microvascular complications. *Oncotarget* 2017;**8**:112675–84.
- 423 doi:10.18632/oncotarget.22699
- 424 15 Liu C, Bai GL, Liu P, et al. Role of EPO and TCF7L2 Gene Polymorphism Contribution
- to the Occurrence of Diabetic Retinopathy. *Dis Markers* 2022;**2022**:6900660.

# 426 doi:10.1155/2022/6900660

427	16	Mankoč Ramuš S, Pungeršek G, Petrovič MG, et al. The GG genotype of erythropoietin
428		rs1617640 polymorphism affects the risk of proliferative diabetic retinopathy in Slovenian
429		subjects with type 2 diabetes mellitus: enemy or ally? Acta Ophthalmol 2021;99:e1382-9.
430		doi:10.1111/AOS.14813
431	17	Sesti LFC, Sbruzzi RC, Polina ER, et al. Association of polymorphisms in the
432		erythropoietin gene with diabetic retinopathy: a case-control study and systematic review
433		with meta-analysis. BMC Ophthalmol 2022;22:250. doi:10.1186/S12886-022-02467-Y
434	18	Tong Z, Yang Z, Patel S, et al. Promoter polymorphism of the erythropoietin gene in
435		severe diabetic eye and kidney complications. Proc Natl Acad Sci USA 2008;105:6998-
436		7003. doi:10.1073/pnas.0800454105
437	19	Chiou TTY, Lee JJ, Wang MC, et al. Genetic disposition and modifiable factors
438		independently associated with anemia in patients with type 2 diabetes mellitus. Diabetes
439		Res Clin Pract 2015;108:164-9. doi:10.1016/j.diabres.2014.12.012
440	20	Popov AF, Schulz EG, Schmitto JD, et al. Relation between renal dysfunction requiring
441		renal replacement therapy and promoter polymorphism of the erythropoietin gene in
442		cardiac surgery. Artif Organs 2010;34:961-8. doi:10.1111/j.1525-1594.2010.01108.x
443	21	Song Q, Zhang Y, Wu Y, et al. Association of erythropoietin gene polymorphisms with
444		retinopathy in a Chinese cohort with type 2 diabetes mellitus. Clin Exp Ophthalmol
445		2015; <b>43</b> :544–9. doi:10.1111/ceo.12505
446	22	Sobrin L, Green T, Sim X, et al. Candidate gene association study for diabetic retinopathy
447		in persons with type 2 diabetes: The candidate gene association resource (CARe). Investig
448		Ophthalmol Vis Sci 2011;52:7593-602. doi:10.1167/IOVS.11-7510/-

- 449 /DCSUPPLEMENTAL
- 450 23 Portolés J, Martín L, Broseta JJ, et al. Anemia in Chronic Kidney Disease: From
- 451 Pathophysiology and Current Treatments, to Future Agents. *Front Med* 2021;**8**:642296.
- 452 doi:10.3389/FMED.2021.642296/BIBTEX
- 453 24 Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive
- 454 chemotactic effect on endothelial cells. *Proc Natl Acad Sci* 1990;**87**:5978–82.
- 455 doi:10.1073/PNAS.87.15.5978
- 456 25 Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. *Endocr Rev*
- 457 2022;**43**:611–53. doi:10.1210/endrev/bnab037
- Li J, Yang M, Yu Z, et al. Kidney-secreted erythropoietin lowers lipidemia via activating
- 459 JAK2-STAT5 signaling in adipose tissue. *EBioMedicine* 2019;**50**:317.
- doi:10.1016/J.EBIOM.2019.11.007
- 461 27 Penna F, Busquets S, Toledo M, et al. Erythropoietin administration partially prevents
- 462 adipose tissue loss in experimental cancer cachexia models. *J Lipid Res* 2013;**54**:3045.
- doi:10.1194/JLR.M038406
- 464 28 Pollock CA, Wyndham R, Collett P V., *et al.* Effects of erythropoietin therapy on the lipid
- 465 profile in end-stage renal failure. *Kidney Int* 1994;**45**:897–902. doi:10.1038/KI.1994.118
- 466 29 Aguiar C, Macleod J, Yip A, et al. Impact of Obesity on Postoperative Outcomes
- 467 following cardiac Surgery (The OPOS study): Rationale and design of an investigator-
- 468 initiated prospective study. *BMJ Open* 2019;9:e023418. doi:10.1136/bmjopen-2018-
- 469 023418
- 470 30 Rychlik W. OLIGO 7 Primer Analysis Software. Humana Press 2007. doi:10.1007/978-1-
- 471 59745-528-2\_2/FIGURES/2\_14\_978-1-59745-528-2

472	31	Andersson B, Lu J, Edwards KE, et al. Method for 96-Well M13 DNA Template
473		Preparations for Large-Scale Sequencing. Biotechniques 1996;20:1022-7.
474		doi:10.2144/96206ST03
475	32	Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis
476		program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999;41:95–8.
477	33	Solé X, Guinó E, Valls J, et al. SNPStats: a web tool for the analysis of association
478		studies. Bioinformatics 2006;22:1928-9. doi:10.1093/BIOINFORMATICS/BTL268
479	34	Reich DE, Cargill M, Bolk S, et al. Linkage disequilibrium in the human genome. Nature
480		2001; <b>411</b> :199–204. doi:10.1038/35075590
481	35	Peters SAE, Muntner P, Woodward M. Sex Differences in the Prevalence of, and Trends
482		in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to
483		2016. Circulation 2019;139:1025-35. doi:10.1161/CIRCULATIONAHA.118.035550
484	36	Lionel AC, Waters R, Sholzberg M, et al. Sex Differences in Anemia and Red Blood Cell
485		Transfusions Among General Internal Medicine Inpatients. Blood 2021;138:1074–1074.
486		doi:10.1182/BLOOD-2021-154106
487	37	Sotomi Y, Hikoso S, Nakatani D, et al. Sex differences in heart failure with preserved
488		ejection fraction. J Am Heart Assoc 2021;10:1–20. doi:10.1161/JAHA.120.018574
489	38	Lanser L, Fuchs D, Kurz K, et al. Physiology and Inflammation Driven Pathophysiology
490		of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment.
491		Nutrients 2021;13:3732. doi:10.3390/NU13113732
492	39	Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives.
493		Bratislava Med J 2021;122:474-88. doi:10.4149/BLL_2021_078
494	40	Gawdat K, Legere S, Wong C, et al. Changes in Circulating Monocyte Subsets (CD16

- 495 Expression) and Neutrophil-to-Lymphocyte Ratio Observed in Patients Undergoing
- 496 Cardiac Surgery. *Front Cardiovasc Med* 2017;4:12. doi:10.3389/fcvm.2017.00012
- 497 41 Katavetin P, Tungsanga K, Eiam-Ong S, et al. Antioxidative effects of erythropoietin.
- 498 *Kidney Int Suppl* 2007;**72**. doi:10.1038/SJ.KI.5002482
- 499 42 Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med* 2005;**352**:1011–23.
- 500 doi:10.1056/NEJMRA041809
- 501 43 Bomford AB, Munro HN. Transferrin and its receptor: their roles in cell function.
- 502 *Hepatology* 1985;**5**:870–5. doi:10.1002/HEP.1840050528
- 503 44 Nairz M, Theurl I, Swirski FK, et al. "Pumping iron"—how macrophages handle iron at
- the systemic, microenvironmental, and cellular levels. *Pflugers Arch* 2017;**469**:397–418.
- 505 doi:10.1007/S00424-017-1944-8
- 506 45 Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors in iron
  507 metabolism. *Cell Cycle* 2008;7:28–32. doi:10.4161/CC.7.1.5145
- 508 46 Zodda D, Giammona R, Schifilliti S. Treatment Strategy for Dyslipidemia in
- 509 Cardiovascular Disease Prevention: Focus on Old and New Drugs. *Pharm 2018, Vol 6,*
- 510 *Page 10* 2018;**6**:10. doi:10.3390/PHARMACY6010010
- 511 47 Eggena P, Willsey P, Jamgotchian N, et al. Influence of recombinant human
- 512 erythropoietin on blood pressure and tissue renin-angiotensin systems. *Am J Physiol*
- 513 1991;**261**:E642–6. doi:10.1152/AJPENDO.1991.261.5.E642
- 514 48 Brier ME, Bunke CM, Lathon P V., *et al.* Erythropoietin-induced antinatriuresis mediated
- 515 by angiotensin II in perfused kidneys. *J Am Soc Nephrol* 1993;**3**:1583–90.
- 516 doi:10.1681/ASN.V391583
- 517 49 Masuda S, Kobayashi T, Chikuma M, et al. The oviduct produces erythropoietin in an

	518	estrogen- and oxygen-dependent manner. Am J Physiol - Endocrinol Metab	
--	-----	--	--

- 519 2000;**278**:E1038–44.
- 520 doi:10.1152/AJPENDO.2000.278.6.E1038/ASSET/IMAGES/LARGE/AEND10610007X.
- 521 JPEG
- 522 50 Peng B, Kong G, Yang C, et al. Erythropoietin and its derivatives: from tissue protection
- 523 to immune regulation. *Cell Death Dis* 2020;**11**. doi:10.1038/S41419-020-2276-8
- 524 51 Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated
  525 cardiovascular disease. *Nat Rev Nephrol 2018 143* 2018;14:185–201.
- 526 doi:10.1038/nrneph.2017.189
- 527 52 Joharapurkar AA, Pandya VB, Patel VJ, et al. Prolyl Hydroxylase Inhibitors: A
- 528 Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. J. Med. Chem.
- 529 2018;**61**:6964–82. doi:10.1021/acs.jmedchem.7b01686
- 530 53 Sakashita M, Tanaka T, Nangaku M. Hypoxia-Inducible Factor-Prolyl Hydroxylase
- 531 Domain Inhibitors to Treat Anemia in Chronic Kidney Disease. In: *Contributions to*
- 532 *Nephrology*. S. Karger AG 2019. 112–23. doi:10.1159/000496531
- 533 54 Northrup V, Perez LJ, Edgett BA, *et al.* Intron retention is a mechanism of erythropoietin
- regulation in brain cell models. *Gene* 2024;**898**:148099. doi:10.1016/j.gene.2023.148099
- 535 55 Northrup V, Maybank A, Carson N, et al. The Value of Next-Generation Sequencing in
- the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice. *Am J Clin*
- 537 *Pathol* 2020;**153**:639–45. doi:10.1093/AJCP/AQZ203
- 538
- 539
- 540

# 541 Tables

### 542 Table 1 - Primers

Target	Primer Name	Sequence 5'→3'		
EPO rs507392	hEPO_1045F_M13	GTAAAACGACGC	GCCAGTGTGGCCC	
		CAAACCATACCT	G	
	hEPO_1981R_M13	CAGGAAACAGCT	TATGACACTGACG	
		GCTTTATCCACA		
EPO rs551238	hEPO_2631F_M13	GTAAAACGACGC	GCCAGTCACCCTG	
		CAAAATTTGATG	CC	
	hEPOdown677R_M13	CAGGAAACAGCT	TATGACAGTGACC	
		CATGATTGCACC		
EPO rs1617640	h_EPOpro1316F_M13	GTAAAACGACGC	GCCAGTAGTGCTG	
		GGATTATAGGTG	TCA	
	h_EPOpro404_M13	CAGGAAACAGCT	TATGACAGAGATG	
		CCTGGGTTGCTG		
M13 sequencing	M13_F	GTAAAACGACGC	GCCAGT	
	M13_R	CAGGAAACAGCTATGAC		
Гаble 2 - Cycling	conditions for gDNA en	d-point PCR.		
Step l	n_EPOpro1316F_M13,	hEPO_1045F_M13,	hEPO_2631F_M13,	
]	n_EPOpro404R_M13	hEPO_1981R_M13	hEPOdown677R_M1	
Initial	10 min @ 95°C	10 min @ 95°C	10 min @ 95°C	

Initial	10 min @ 95°C	10 min @ 95°C	10 min @ 95°C
Denaturation			
Denaturation	30 sec @ 95°C	30 sec @ 95°C	30 sec @ 95°C
Annealing	30 sec @ 58°C	30 sec @ 58°C	30 sec @ 58°C
Extension	45 sec @ 72°C	60 sec @ 72°C	90 sec @ 72°C
Cycles	35	35	35
Final	10 min @ 72°C	10 min @ 72°C	10 min @ 72°C
Extension			

546 Min=minutes, sec=seconds @=at

547

543 544 545

	Total		Anemia		Γ	<b>)</b> yslipidemia		Hypertension		
	(n=95)	Cases (n=31)	Controls (n=64)	p-value	Cases (n=66)	Controls (n=29)	p-value	Cases (n=70)	Controls (n=25)	p-value
Age (years)	$63.5\pm6.6$	$65.1\pm5.8$	$62.7\pm 6.8$	0.5	$64.3\pm6.3$	$61.7\pm6.8$	0.03	$64.2\pm6.9$	$61.6\pm5.3$	0.04
Females	30 (32%)	16 (52%)	14 (22%)		17 (26%)	13 (45%)		17 (24%)	13 (52%)	
BMI (kg/m <sup>2</sup> )	$31.8\pm7.3$	$34.4 \pm 9.4$	$30.5\pm5.6$	0.007	$31.3\pm6.0$	$32.7\pm9.6$	0.70	$31.4\pm6.3$	$32.8\pm9.6$	0.10
Hemoglobin (g/L)	$134.8 \pm 14.7$	117.8 ±	142.6 ±	<0.0001	$134.8 \pm$	$135.0 \pm$	0.60	$134.9 \pm$	$134.7 \pm$	0.82
		11.5	7.8		14.6	14.8		15.2	12.9	
Hematocrit (L/L)	$0.40 \pm 0.04$	$0.35 \pm$	$0.42 \pm$	<0.0001	$0.40 \pm$	$0.40 \pm$	0.46	$0.40 \pm$	$0.40 \pm$	0.75
MCV (fl)	$90.1 \pm 4.3$	0.03	<b>0.02</b> 00 0 + 3 8	0.052	0.04	0.04	0.054	0.04 $00.3 \pm 4.3$	0.03	0.55
$PDC(=10^{12}/I)$	$14 \pm 0.1$		$16 \pm 0.2$	<pre>0.052</pre>	$0.4 \pm 4.2$	$1.7 \pm 3.7$	0.034	$10.3 \pm 4.3$	$45 \pm 0.2$	0.55
RBC(X10/L)	$4.4 \pm 0.4$	$4.0 \pm 0.4$	$4.0 \pm 0.3$	<0.0001	$4.3 \pm 0.4$	$4.4 \pm 0.4$	0.81	$4.4 \pm 0.3$	$4.3 \pm 0.3$	0.55
HbA1c (%)	$6.1 \pm 1.0$	$6.2 \pm 1.3$	$6.0 \pm 0.9$	0.68	$6.2 \pm 1.1$	$5.8 \pm 0.8$	0.29	$6.1 \pm 1.1$	$5.8 \pm 0.8$	0.42
Cholesterol	$4.1 \pm 1.2$	$4.0 \pm 1.1$	$4.1 \pm 1.2$	0.86	$3.9 \pm 1.1$	$4.5\pm1.1$	0.06	$3.9 \pm 1.2$	$4.4 \pm 1.1$	0.52
(mmol/L)										
HDL (mmol/L)	$1.2 \pm 0.4$	$1.2 \pm 0.4$	$1.2 \pm 0.3$	0.66	$1.2 \pm 0.3$	$1.4\pm0.3$	0.057	$1.2 \pm 0.4$	$1.3\pm0.3$	0.26
LDL (mmol/L)	$2.1\pm0.9$	$2.1\pm0.9$	$2.1\pm0.9$	0.89	$2.0\pm0.8$	$\textbf{2.5} \pm \textbf{1.0}$	0.03	$2.0\pm0.9$	$2.5\pm1.0$	0.51
LDL/HDL	$1.8\pm0.8$	$1.7\pm0.8$	$1.8\pm0.7$	0.63	$1.7\pm0.7$	$1.9\pm0.7$	0.38	$1.7\pm0.7$	$1.9\pm0.8$	0.92
Non-HDL (mmol/L)	2.9 ± 1.1	$2.8 \pm 1.0$	$2.9 \pm 1.1$	0.75	$2.7 \pm 1.1$	$3.1\pm1.0$	0.17	$2.8 \pm 1.1$	$3.1 \pm 1.0$	0.79
Triglycerides	$1.6 \pm 1.1$	$1.8 \pm 1.2$	$1.6 \pm 1.0$	0.58	$1.7 \pm 1.2$	$1.3\pm0.6$	0.27	$1.7 \pm 1.2$	$1.4 \pm 0.6$	0.59
(mmol/L)										
NLR	$3.9\pm5.1$	$6.1 \pm 8.5$	$2.9\pm1.2$	0.11	$3.8\pm4.6$	$4.1\pm6.0$	0.47	$4.2\pm5.7$	$3.1 \pm 2.1$	0.55

Table 3. Demographics of the OPOS sub-cohort

BMI=Body mass index, HDL=high-density lipoprotein, LDL=low-density lipoprotein, MCV=Mean Corpuscular Volume, RBC=red blood cells (erythrocytes), NLR=Neutrophiles Lymphocytes ratio. p-value for continuous variable (BMI, Hemoglobin, Hematocrit, HbA1c, Cholesterol, HDL, LDL, MCV, Triglycerides, RBC, NLR) expressed as mean ±SD, p-value calculated using t-test. Categorical variable (Sex) expressed as number of cases (percentage of group), p-value calculated using Chi-square test. Significant p-value of <0.05 are bolded.

	Anemia					Dyslipidemia					Hypertension			
	Cases	Control	OR	P-	Cases	Control	OR	P-	Cases	Control	OR	P-value		
			(95%	value			(95%	value			(95%			
			CI)				CI)				CI)			
	rs1617640													
AA	8	30	2.83	0.065	29	9	0.41	0.11	28	10	1.24	0.73		
AC	11	21	(0.93-		23	9	(0.14-		24	8	(0.36-			
CC	12	12	8.60)		13	11	1.23)		18	6	4.29)			
Α	27	81	1.96	0.04	81	27	0.64	0.15	80	28	1.24	0.54		
С	35	45	(1.02-		49	31	(0.34-		60	20				
			3.79)				1.19)				(0.62-			
											2.48)			
							r	rs507392	2					
AA	7	29	2.58	0.12	28	8	0.29	0.048	27	9	1.21	0.79		
AG	8	23	(0.78-		23	8	(0.09-		25	6	(0.00)			
GG	8	11	8.55)		10	9	1.00)		15	4	(0.29-			
		01	1.72	0.10	70	24	0.52	0.066	70	24	4.94)	0.51		
A	22	81	1./3	0.12		24	0.53	0.066	/9		1.29	0.51		
G	24	45	(0.80 - 2.46)		43	26	(0.27 - 1.05)		55	14	(0.00 - 2.81)			
			5.40)				1.05)	a551739	2		2.81)			
тт	0	22	2.22	0.19	20	10	0.26	<u>0 11</u>	20	11	1.01	0.43		
	0	32	(0.68)	0.10	$\frac{30}{22}$	10	$(0.20)^{-1}$	0.11	29		(0.30)	0.43		
	9	22	(0.08 - 7.07)			8	(0.11 - 1.27)			/	8 30)			
GG	- /	10	1.71)	0.15	9	8	1.27)		14	3	0.50)	0.25		
<u>T</u>	25	86	1.63	0.17	83	28	0.66	0.23	82	29	1.55	0.27		
G	23	42	(0.81-		41	24	(0.33 - 1.20)		52	13	(0.70			
			3.25)				1.30)				(0.70-			
											3.40)			

Table 4. Association of anemia, dyslipidemia and hypertension by genotype

OR=Odds Ratio, Cl=confidence limit

Haplotype		Anemia			Dyslipidemia		Hypertension			
	Frequency	OR (95% CI)	p-value	Frequency	OR (95% CI)	p-value	Frequency	OR (95% CI)	p-value	
AAT	0.5674	1.00	n/a	0.5673	1.00	n/a	0.5672	1.00	n/a	
CGG	0.3837	1.98 (1.01-3.91)	0.051	0.3848	0.72 (0.36-1.44)	0.36	0.3836	1.45 (0.69-3.05)	0.33	
CGT	0.0311	3.05 (0.38-24.72)	0.3	0.0298	0.05 (0.00-0.51)	0.014	0.329	0.39 (0.05-2.99)	0.37	
GHA p-		0.19			0.031		0.36			
value										

 Table 5. Haplotype association

 value

 OR=Odds ratio, Cl=confidence limit, GHA=global haplotype association, n/a=not applicable

	Anemia							Dyslipidemia	Hypertension					
Sex	Gen.	Case	Ctrl	Ctrl OR (95% CI) Int.		Case	Case Ctr OR (95% CI) Int.		Int.	Case	Ctr	OR (95% CI)	Int.	
						rs1	61764	0						
F	A/A	4	5	1.00	0.99	5	4	1.00	0.5	3	5	1.00	0.1	
	A/C	6	6	1.69 (0.25-11.25)	-	8	4	2.19 (0.33-14.68)	-	8	2	9.38 (0.90-98.15)	-	
	C/C	6	3	4.03 (0.45-35.91)	-	4	5	0.82 (0.11-6.28)	-	4	2	6.48 (0.47-89.67)	-	
Μ	A/A	4	25	1.00	_	24	5	1.00	-	24	5	1.00	-	
	A/C	5	15	1.82 (0.39-8.43)	_	15	5	0.55 (0.13-2.33)	-	16	4	0.50 (0.10-2.55)	-	
	C/C	6	9	3.80 (0.79-18.35)	-	9	6	0.27 (0.06-1.27)	-	12	2	0.54 (0.07-4.09)	-	
						rs	507392	2						
F	A/A	3	4	1.00	0.65	4	3	1.00	0.65	2	5	1.00	0.03	
	A/G	3	7	0.73 (0.08-6.54)	-	7	3	1.88 (0.21-16.79)	-	8	2	18.48 (1.50-227.27)	-	
	G/G	4	3	3.55 (0.31-40.81)	_	3	4	0.43 (0.04-5.13)	-	5	2	15.43 (1.02-233.40)	-	
Μ	A/G	4	25	1.00	_	24	5	1.00	-	25	4	1.00	-	
	G/G	5	16	1.89 (0.41-8.82)	-	16	5	0.55 (0.13-2.33)	-	17	4	0.51 (0.10-2.63)	-	
	C/C	4	8	2.78 (0.51-15.09)	_	7	5	0.21 (0.04-1.11)	-	10	2	0.45 (0.06-3.49)	-	
						rs	551238	8						
F	T/T	4	4	1.00	0.57	4	4	1.00	0.42	2	6	1.00	0.02	
	T/G	4	7	0.59 (0.08-4.36)	-	8	3	3.22 (0.40-25.64)	-	9	2	19.16 (1.84-199.49)	-	
	G/G	3	3	1.80 (0.17-19.69)	-	2	4	0.55 (0.05-6.61)	-	4	2	11.33 (0.84-153.49)	-	
Μ	T/T	4	28	1.00	_	26	6	1.00	-	27	5	1.00	-	
	T/G	5	15	2.26 (0.48-10.58)	_	15	5	0.62 (0.15-2.52)	-	15	5	0.47 (0.11-2.06)	-	
	G/G	4	7	3.40 (0.61-18.82)	-	7	4	0.32 (0.06-1.72)	-	10	1	1.11 (0.10-12.27)	-	

 Table 6. Sex differences

F=female, M=male, Geno=Genotype, Ctrl=Control, OR=odds ratio, Int=Interaction p-value, Cl=confidence limit



**Figure 1. Plasma EPO concentration is decreased in rs161640 CC genotype and rs507392 GG genotype, but not rs51238.** Transferrin and Hepcidin showed no genotype correlation although there does appear to be variation in Ferritin it does not reach significance. Plasma concentrations were determined using ELISA assays with outliers marked by circles and excluded from statistical analysis. Outliers were determined by ROUT test and *a priori* as two standard deviations from the mean or else being below the lower limit of detection of the ELISA. ANOVA was used to determine significance with p-values < 0.05 deemed significant.